Genetic predisposition to myeloproliferative neoplasms implicates hematopoietic stem cell biology
Erik L Bao,
Satish K Nandakumar,
Alexander G. Bick,
Olga I Gan,
Tuomo T. J. Kiiskinen,
Aitzkoa L de Lapuente Portilla,
Christopher P Nelson,
23andMe Research Team,
Peter WF Wilson,
J. Michael Gaziano,
Nilesh J. Samani,
Million Veteran Program,
Benjamin M. Neale,
John E. Dick,
Christopher J. O’Donnell,
Vijay G. Sankaran
Posted 08 Oct 2019
bioRxiv DOI: 10.1101/790626
Posted 08 Oct 2019
Myeloproliferative neoplasms (MPNs) are blood cancers characterized by excessive production of mature myeloid cells that result from the acquisition of somatic driver mutations in hematopoietic stem cells (HSCs). While substantial progress has been made to define the causal somatic mutation profile for MPNs, epidemiologic studies indicate a significant heritable component for the disease that is among the highest known for all cancers. However, only a limited set of genetic risk loci have been identified, and the underlying biological mechanisms leading to MPN acquisition remain unexplained. Here, to define the inherited risk profile, we conducted the largest genome-wide association study of MPNs to date (978,913 individuals with 3,224 cases) and identified 14 genome-wide significant loci, as well as a polygenic signature that increases the odds for disease acquisition by nearly 3-fold between the top and median deciles. Interestingly, we find a shared genetic architecture between MPN risk and several hematopoietic traits spanning distinct lineages, as well as an association between increased MPN risk and longer leukocyte telomere length, collectively implicating HSC function and self-renewal. Strikingly, we find a significant enrichment for risk variants mapping to accessible chromatin in HSCs compared with other hematopoietic populations. Finally, gene mapping identifies modulators of HSC biology and targeted variant-to-function analyses suggest likely roles for CHEK2 and GFI1B in altering HSC function to confer disease risk. Overall, we demonstrate the power of human genetic studies to illuminate a previously unappreciated mechanism for MPN risk through modulation of HSC function.
- Downloaded 1,235 times
- Download rankings, all-time:
- Site-wide: 15,822
- In genetics: 771
- Year to date:
- Site-wide: 31,023
- Since beginning of last month:
- Site-wide: 45,903
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!